Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KPRXNASDAQ:NXTCNASDAQ:PHXMNASDAQ:PLRZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKPRXKiora Pharmaceuticals$3.21-1.4%$3.04$2.51▼$5.55$9.76M-0.6731,135 shs10,269 shsNXTCNextCure$0.43-2.6%$0.47$0.22▼$1.82$12.18M1.04103,214 shs78,506 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/APLRZPolyrizon$0.35-6.6%$0.50$0.25▼$4.80$1.47MN/A5.56 million shs51.72 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKPRXKiora Pharmaceuticals0.00%-2.11%+22.18%-9.72%-25.73%NXTCNextCure0.00%+0.79%+53.26%-39.62%-72.97%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%PLRZPolyrizon0.00%-62.90%-2.12%-63.26%+37,469,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKPRXKiora Pharmaceuticals3.5991 of 5 stars3.85.00.00.04.01.70.6NXTCNextCure4.7804 of 5 stars3.55.00.04.34.41.71.3PHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKPRXKiora Pharmaceuticals 3.50Strong Buy$10.00211.92% UpsideNXTCNextCure 3.00Buy$3.50705.89% UpsidePHXMPHAXIAM Therapeutics 0.00N/AN/AN/APLRZPolyrizon 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PLRZ, NXTC, PHXM, and KPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025KPRXKiora PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/17/2025NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.003/7/2025NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $3.00(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKPRXKiora Pharmaceuticals$16M0.61N/AN/A$7.14 per share0.45NXTCNextCureN/AN/AN/AN/A$4.10 per shareN/APHXMPHAXIAM Therapeutics$32.66M0.32N/AN/A$7.98 per share0.39PLRZPolyrizonN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKPRXKiora Pharmaceuticals-$12.51M-$2.90N/AN/AN/AN/A21.32%16.39%N/ANXTCNextCure-$62.72M-$1.76N/AN/AN/AN/A-62.50%-53.67%N/APHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/APLRZPolyrizonN/AN/A0.00∞N/AN/AN/AN/AN/ALatest PLRZ, NXTC, PHXM, and KPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025KPRXKiora Pharmaceuticals-$0.77-$0.52+$0.25-$0.52$0.75 millionN/A5/1/2025Q1 2025NXTCNextCure-$0.40-$0.39+$0.01-$0.39N/AN/A3/25/2025Q4 2024KPRXKiora Pharmaceuticals-$0.64-$1.04-$0.40-$1.04$0.75 million$0.75 million3/6/2025Q4 2024NXTCNextCure-$0.34-$0.41-$0.07-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKPRXKiora PharmaceuticalsN/A8.978.97NXTCNextCureN/A9.079.07PHXMPHAXIAM Therapeutics0.231.78N/APLRZPolyrizonN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKPRXKiora Pharmaceuticals76.97%NXTCNextCure42.65%PHXMPHAXIAM Therapeutics0.40%PLRZPolyrizonN/AInsider OwnershipCompanyInsider OwnershipKPRXKiora Pharmaceuticals0.94%NXTCNextCure17.90%PHXMPHAXIAM Therapeutics1.94%PLRZPolyrizonN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKPRXKiora Pharmaceuticals103.04 million2.97 millionNot OptionableNXTCNextCure9028.05 million24.28 millionOptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataPLRZPolyrizonN/A4.19 millionN/AN/APLRZ, NXTC, PHXM, and KPRX HeadlinesRecent News About These CompaniesPolyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail InterestMay 5, 2025 | msn.comPolyrizon reports safety study results for PL-14 Allergy Blocker formulationApril 26, 2025 | markets.businessinsider.comPolyrizon Ltd.: Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue ModelApril 25, 2025 | finanznachrichten.dePolyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue ModelApril 25, 2025 | globenewswire.comPolyrizon Ltd. Shareholders Approve Key Amendments at Annual MeetingApril 17, 2025 | tipranks.comPolyrizon Faces Nasdaq Compliance ChallengeApril 11, 2025 | tipranks.comPolyrizon Receives Nasdaq Notification Regarding Minimum Bid RequirementsApril 11, 2025 | globenewswire.comPolyrizon entered into agreement with branding, trademark consultancy firmApril 3, 2025 | markets.businessinsider.comPolyrizon Partners with Branding Firm for Strategic Brand DevelopmentApril 2, 2025 | tipranks.comPolyrizon Engages Leading Branding Firm for Strategic Brand DevelopmentApril 2, 2025 | globenewswire.comPolyrizon Ltd. Secures $17 Million in Private Placement to Advance Hydrogel TechnologyApril 1, 2025 | tipranks.comPolyrizon Ltd. Announces Closing of $17.0 Million Private PlacementApril 1, 2025 | globenewswire.comPolyrizon announces $17M private placementMarch 31, 2025 | markets.businessinsider.comPolyrizon Ltd. Announces $17.0 Million Private PlacementMarch 31, 2025 | globenewswire.comPolyrizon Advances Clinical Strategy For PL-14 Allergy Blocker Ahead Of FDA MeetingMarch 29, 2025 | nasdaq.comPolyrizon structures clinical strategy for allergy blocker PL-14March 28, 2025 | markets.businessinsider.comPolyrizon Prepares Clinical Strategy for Allergy Blocker PL-14March 27, 2025 | tipranks.comPolyrizon Ltd.: Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue TreatmentMarch 27, 2025 | finanznachrichten.dePolyrizon begins preclinical studies for seizure treatmentMarch 27, 2025 | uk.investing.comPolyrizon begins BZDs studies for treating ARS and status epilepticusMarch 27, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePLRZ, NXTC, PHXM, and KPRX Company DescriptionsKiora Pharmaceuticals NASDAQ:KPRX$3.21 -0.04 (-1.35%) Closing price 03:58 PM EasternExtended Trading$3.23 +0.02 (+0.75%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.NextCure NASDAQ:NXTC$0.43 -0.01 (-2.62%) Closing price 04:00 PM EasternExtended Trading$0.43 0.00 (-0.53%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 05/9/2025PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.Polyrizon NASDAQ:PLRZ$0.35 -0.02 (-6.59%) As of 04:00 PM EasternPolyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
